Zalutumumab

Zalutumumab is a monoclonal antibody used in the treatment of certain types of cancer. It specifically targets the epidermal growth factor receptor (EGFR), which is overexpressed in various carcinomas. Zalutumumab is designed to inhibit the growth and proliferation of cancer cells by blocking the EGFR pathway.

Mechanism of Action

Zalutumumab binds to the epidermal growth factor receptor (EGFR) on the surface of cancer cells. By attaching to EGFR, it prevents the receptor from being activated by its natural ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). This inhibition disrupts the downstream signaling pathways that promote cell division and survival, leading to reduced tumor growth and potentially inducing apoptosis in cancer cells.

Clinical Use

Zalutumumab has been investigated for use in the treatment of squamous cell carcinoma of the head and neck (SCCHN). It is typically administered to patients who have not responded to standard therapies, including chemotherapy and radiation therapy.

Side Effects

Common side effects of Zalutumumab include skin rash, diarrhea, and fatigue. More severe side effects can include infusion reactions, hypomagnesemia, and interstitial lung disease.

Development and Approval

Zalutumumab was developed by the Danish biotechnology company Genmab. It has undergone various clinical trials to assess its efficacy and safety in treating different types of cancer. However, as of the latest updates, it has not received widespread regulatory approval for general use.

Related Monoclonal Antibodies

• Cetuximab
• Panitumumab
• Nimotuzumab

See Also

• Monoclonal antibody therapy
• Targeted therapy
• Cancer treatment

External Links

‎